drugset / Trial / NCT00813020

A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects

NCT00813020

Phase 1 Completed 44 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, NN9535, administered in healthy male subjects in equal doses.

Timeline

Start
2009-01
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg/ml Subcutaneous
Subject Semaglutide Peptide 3 mg/ml Subcutaneous
Subject Semaglutide Peptide 10 mg/ml Subcutaneous